LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Strona główna・Stock List・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Closed

SectorHealthcare

166.05 1.65

Buy Sell

Overview

Share price change

24h

Current

Min

159.38

Max

168.72

Key metrics
By Trading Economics
Income	2.9M 56M
Sales	-27M 1B
EPS	2.43
Profit margin	5.529
Employees	18,700
EBITDA	-23M 198M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+26.93% upside

Dividends
By Dow Jones
Next Earnings	6 maj 2026

Market Stats
By TradingEconomics
Market Cap	-862M 7.9B
Previous open	164.4
Previous close	166.05

News Sentiment

By Acuity

95%

149 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

117.16 / 144.77 Support & Resistance

Charles River Laboratories International Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 lut 2026, 23:07 UTC

Earnings

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 23:01 UTC

Earnings

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:59 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 lut 2026, 22:42 UTC

Earnings

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 lut 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 lut 2026, 23:48 UTC

Earnings

OCBC's Fourth-Quarter Net Profit Rose on Higher Non-Interest Income

24 lut 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 lut 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 lut 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 lut 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24 lut 2026, 23:16 UTC

Earnings

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 lut 2026, 23:13 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 lut 2026, 23:12 UTC

Earnings

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 lut 2026, 23:10 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 lut 2026, 23:08 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 lut 2026, 23:07 UTC

Earnings

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 lut 2026, 22:52 UTC

Earnings

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 lut 2026, 22:46 UTC

Earnings

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 lut 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Warner Receives New Bid From Paramount -- 3rd Update

24 lut 2026, 22:29 UTC

Earnings

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 lut 2026, 22:28 UTC

Earnings

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 lut 2026, 22:27 UTC

Earnings

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 lut 2026, 22:25 UTC

Earnings

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 lut 2026, 22:24 UTC

Earnings

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 lut 2026, 22:23 UTC

Earnings

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 lut 2026, 22:22 UTC

Earnings

Woolworths Interim Dividend 45 Australian Cents/Share

24 lut 2026, 22:22 UTC

Earnings

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

Peer Comparison

Price change

Charles River Laboratories International Inc Forecast

Price Target

By TipRanks

26.93% upside

12 Months Forecast

Average 207.56 USD 26.93%

High 265 USD

Low 175 USD

Based on 11 Wall Street analysts offering 12 month price targets forCharles River Laboratories International Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Charles River Laboratories International Inc - Dist in the past 3 months.

Technical Score

By Trading Central

117.16 / 144.77Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

149 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.